The Value of Peripheral Arterial Resistive Index in Evaluation of Tissue Perfusion in Patients With Septic Shock
1 other identifier
observational
50
1 country
1
Brief Summary
In patients with septic shock, routine arterial blood pressure and central venous pressure are monitored in ICU. Conventional methods such as blood pressure and central venous pressure in septic patients cannot provide sufficient information in the follow-up due to the body's compensation mechanisms. The systemic vascular resistance index, which can be measured invasively or non-invasively with advanced hemodynamic monitoring methods, is a parameter that plays an important role in the management of septic patients. Resistive index (Pourcelot Index) is an ultrasonic measurement method used to evaluate tissue perfusion and microcirculation. Since peripheral tissue perfusion is impaired in septic patients, the investigators think resistive index may be useful for management of sepsis. There are studies in the literature on the use of resistive index in the follow-up of patients. The study will be about whether there is a correlation between the systemic vascular resistance index measured by cardiac output measurement, which is one of the advanced monitoring methods routinely used in the group requiring mechanical ventilation support in patients with septic shock, and the peripheral arterial resistive index, which is routinely used to evaluate tissue perfusion and microcirculation.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for all trials
Started Apr 2022
Shorter than P25 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
April 1, 2022
CompletedPrimary Completion
Last participant's last visit for primary outcome
March 31, 2023
CompletedStudy Completion
Last participant's last visit for all outcomes
March 31, 2023
CompletedFirst Submitted
Initial submission to the registry
May 27, 2023
CompletedFirst Posted
Study publicly available on registry
June 13, 2023
CompletedJune 13, 2023
June 1, 2023
12 months
May 27, 2023
June 12, 2023
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
correlation of snuffbox radial artery resistive index and systemic vascular resistance index
correlation of snuffbox radial artery resistive index and systemic vascular resistance index
1 hour. As soon as patient meets all of the inclusion criteria
Secondary Outcomes (5)
correlation of snuffbox radial artery resistive index and pleth variability index
1 hour. As soon as patient meets all of the inclusion criteria
correlation of snuffbox radial artery resistive index and delta stroke volume index
1 hour. As soon as patient meets all of the inclusion criteria
correlation of snuffbox radial artery resistive index and diastolic shock index
1 hour. As soon as patient meets all of the inclusion criteria
correlation of snuffbox radial artery resistive index and central vena cava oxygen saturation and partial carbon dioxide pressure gap
1 hour. As soon as patient meets all of the inclusion criteria
correlation of snuffbox radial artery resistive index and cardiac power index
1 hour. As soon as patient meets all of the inclusion criteria
Study Arms (1)
septic shock patients
mechanically ventilated septic shock patients
Interventions
Baxter Starling Monitor for measuring cardiac output and systemic vascular resistance (SVRI) which is using bioreactance technology. We need to place four electrodes on chest wall (upper left, upper right, down left, down right) and input monitor demographic parameters. Also enter mean arterial pressure (MAP) for calculating SVRI so we input MAP every minute.Patient bed set as 45 degree head elevated and legs 0 degree. Just after start measuring, monitor needs to synchronize itself for patient. After synchronisation we start fluid challenge with passive leg raising option. This test has two stages. First stage calculating baseline parameters which takes 3 minutes and second stage is measuring difference with fluid challenge which also takes 3 minutes. At the end of first stage monitor shows to perform passive leg raise and we perform trendelenburg maneuver till head comes to 0 degree. After second stage measurement has finished.
We use ultrasonography at the same time with cardiac output monitor in both stages. First we determine the location of radial artery at wrist snuffbox at 1.5 centimeters depth with linear probe and confirm pulsatile flow with color mode. In Starling's baseline stage we measure and calculate resistive index with doppler P-mode in triplex setting 3 times. When received 3 same result successively we noted as SBRI-1. Second measurement is initiated at last 30 seconds of passive leg raising as described before and we noted our measurement as SBRI-2
During all stages Masimo Rad-87 rainbow probe is placed patients index or middle finger and we note PVI-1 and PVI-2 at the same time with SBRI-1 and SBRI-2
Eligibility Criteria
Patients who admited to intensive care unit of Bezmialem Vakıf Univesity Hospital
You may qualify if:
- \>18 years old
- admitted to intensive care for septic shock
- mechanical ventilated
- non spontaneous breathing
- applied invasive artery cannulation (radial, femoral, brachial)
- applied central venous catheter (jugular, subclavian)
- SOFA score\>2
- Receiving vasopressor/inotrope support to achieve MAP ≥65 mmHg
- Blood lactate \>2mmol/L
You may not qualify if:
- \<18 years old
- Hypothermia (\<35C)
- Atrial fibrilation/flutter
- Pace-maker
- Severe aort valve insufficiency
- History of aortic and the great arteries adjacent to the aortic arch surgery
- Bilateral radial artery puncture in last 12 hours
- Peripheral artery disease
- Extremity amputation (leg or arm)
- Wound on forearm
- Continous Renal Replacement Therapy
- Spontaneous breath effort
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Bezmialem Vakıf University
Fatih, Istanbul, 34093, Turkey (Türkiye)
Related Publications (12)
Singer M, Deutschman CS, Seymour CW, Shankar-Hari M, Annane D, Bauer M, Bellomo R, Bernard GR, Chiche JD, Coopersmith CM, Hotchkiss RS, Levy MM, Marshall JC, Martin GS, Opal SM, Rubenfeld GD, van der Poll T, Vincent JL, Angus DC. The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). JAMA. 2016 Feb 23;315(8):801-10. doi: 10.1001/jama.2016.0287.
PMID: 26903338BACKGROUNDAngus DC, Linde-Zwirble WT, Lidicker J, Clermont G, Carcillo J, Pinsky MR. Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit Care Med. 2001 Jul;29(7):1303-10. doi: 10.1097/00003246-200107000-00002.
PMID: 11445675BACKGROUNDCohen J, Vincent JL, Adhikari NK, Machado FR, Angus DC, Calandra T, Jaton K, Giulieri S, Delaloye J, Opal S, Tracey K, van der Poll T, Pelfrene E. Sepsis: a roadmap for future research. Lancet Infect Dis. 2015 May;15(5):581-614. doi: 10.1016/S1473-3099(15)70112-X. Epub 2015 Apr 19.
PMID: 25932591BACKGROUNDRudd KE, Johnson SC, Agesa KM, Shackelford KA, Tsoi D, Kievlan DR, Colombara DV, Ikuta KS, Kissoon N, Finfer S, Fleischmann-Struzek C, Machado FR, Reinhart KK, Rowan K, Seymour CW, Watson RS, West TE, Marinho F, Hay SI, Lozano R, Lopez AD, Angus DC, Murray CJL, Naghavi M. Global, regional, and national sepsis incidence and mortality, 1990-2017: analysis for the Global Burden of Disease Study. Lancet. 2020 Jan 18;395(10219):200-211. doi: 10.1016/S0140-6736(19)32989-7.
PMID: 31954465BACKGROUNDVincent JL, Sakr Y, Sprung CL, Ranieri VM, Reinhart K, Gerlach H, Moreno R, Carlet J, Le Gall JR, Payen D; Sepsis Occurrence in Acutely Ill Patients Investigators. Sepsis in European intensive care units: results of the SOAP study. Crit Care Med. 2006 Feb;34(2):344-53. doi: 10.1097/01.ccm.0000194725.48928.3a.
PMID: 16424713BACKGROUNDLevy MM, Dellinger RP, Townsend SR, Linde-Zwirble WT, Marshall JC, Bion J, Schorr C, Artigas A, Ramsay G, Beale R, Parker MM, Gerlach H, Reinhart K, Silva E, Harvey M, Regan S, Angus DC. The Surviving Sepsis Campaign: results of an international guideline-based performance improvement program targeting severe sepsis. Intensive Care Med. 2010 Feb;36(2):222-31. doi: 10.1007/s00134-009-1738-3. Epub 2010 Jan 13.
PMID: 20069275BACKGROUNDLevy MM, Artigas A, Phillips GS, Rhodes A, Beale R, Osborn T, Vincent JL, Townsend S, Lemeshow S, Dellinger RP. Outcomes of the Surviving Sepsis Campaign in intensive care units in the USA and Europe: a prospective cohort study. Lancet Infect Dis. 2012 Dec;12(12):919-24. doi: 10.1016/S1473-3099(12)70239-6. Epub 2012 Oct 26.
PMID: 23103175BACKGROUNDKaukonen KM, Bailey M, Suzuki S, Pilcher D, Bellomo R. Mortality related to severe sepsis and septic shock among critically ill patients in Australia and New Zealand, 2000-2012. JAMA. 2014 Apr 2;311(13):1308-16. doi: 10.1001/jama.2014.2637.
PMID: 24638143BACKGROUNDReuter DA, Chappell D, Perel A. The dark sides of fluid administration in the critically ill patient. Intensive Care Med. 2018 Jul;44(7):1138-1140. doi: 10.1007/s00134-017-4989-4. Epub 2017 Nov 11. No abstract available.
PMID: 29128963BACKGROUNDKox M, Pickkers P. "Less is more" in critically ill patients: not too intensive. JAMA Intern Med. 2013 Jul 22;173(14):1369-72. doi: 10.1001/jamainternmed.2013.6702.
PMID: 23752755BACKGROUNDGroeneveld AB, Nauta JJ, Thijs LG. Peripheral vascular resistance in septic shock: its relation to outcome. Intensive Care Med. 1988;14(2):141-7. doi: 10.1007/BF00257468.
PMID: 3361019BACKGROUNDBan K, Kochi K, Imai K, Okada K, Orihashi K, Sueda T. Novel Doppler technique to assess systemic vascular resistance: the snuffbox technique. Circ J. 2005 Jun;69(6):688-94. doi: 10.1253/circj.69.688.
PMID: 15914947BACKGROUND
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Design
- Study Type
- observational
- Observational Model
- CASE ONLY
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
May 27, 2023
First Posted
June 13, 2023
Study Start
April 1, 2022
Primary Completion
March 31, 2023
Study Completion
March 31, 2023
Last Updated
June 13, 2023
Record last verified: 2023-06